Noteworthy, different CDK4/6i treatment strategies may influence the median onset time of CDK4/6i-related myocardial infarction, hypertension, and ATE (p < 0.05) (Figures 5D,F,G). This evidence concerns the gene CDK4 and myocardial infarction.